Evidence map›Paper›PMID 38795271›Full record

SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2024

Phosphodiesterase-5 inhibitors use and the risk of alzheimer's disease: a systematic review and meta-analysis.

Moaz Elsayed Abouelmagd, Maickel Abdelmeseh, Amr Elrosasy, Yousef Hesham Saad, Asmaa Zakria Alnajjar, Mahmoud Eid, Atef Hassan, Abdallah Abbas

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Moaz Elsayed AbouelmagdFaculty of Medicine, Cairo University, Cairo, Egypt. moaz_s_sayed@studendts.kasralainy.edu.eg.ORCID http://orcid.org/0000-0002-0511-2429
Maickel AbdelmesehFaculty of Medicine, Alexandria University, Alexandria, Egypt.ORCID http://orcid.org/0000-0002-4703-4203
Amr ElrosasyFaculty of Medicine, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0000-0002-5592-3908
Yousef Hesham SaadFaculty of Medicine, Mansoura University, Mansoura, Egypt.ORCID http://orcid.org/0000-0002-3303-7737
Asmaa Zakria AlnajjarFaculty of Medicine, Al- Al-Azhar University, Gaza, Palestine.ORCID http://orcid.org/0000-0002-1254-4289
Mahmoud EidFaculty of Medicine, October 6Th University, Cairo, Egypt.ORCID http://orcid.org/0009-0001-2255-7454
Atef HassanFaculty of Medicine, Al-Azhar University, Damietta, Egypt.ORCID http://orcid.org/0000-0003-3393-9105
Abdallah AbbasFaculty of Medicine, Al-Azhar University, Damietta, Egypt.ORCID http://orcid.org/0000-0001-5101-5972

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe management of Alzheimer's disease (AD) poses considerable challenges, necessitating the pursuit of innovative therapeutic approaches. Recent research has spotlighted the promising role of phosphodiesterase type 5 inhibitors (PDE5Is) in reducing the prevalence of AD, utilizing their vasodilatory properties to suggest a potential neuroprotective effect. This meta-analysis and systematic review aims to assess the relationship between the use of PDE5Is and the risk of AD.

methodsA detailed examination was carried out across several electronic databases till March 2024, including PubMed, Web of Science, Scopus, CENTRAL, and Embase. The focus was on identifying studies that compare the occurrence of AD among PDE5I users vs non-users. Through a random-effects model, pooled hazard ratios (HRs) were calculated, in alignment with guidelines from the Cochrane Handbook for Systematic Reviews and Meta-Analysis and the PRISMA standards.

resultsThis analysis included six studies, cumulating a participant count of 8,337,313, involving individuals treated with sildenafil, tadalafil, and vardenafil, against a control group undergoing other or no treatments. The cumulative HR for AD risk among PDE5I users versus the control group was 0.53 (95% CI: 0.32-0.86, p = 0.008), signaling a markedly reduced likelihood of AD development in the PDE5I group. Particularly, sildenafil usage showed a significant risk reduction (HR: 0.46, 95% CI: 0.31-0.70, p < 0.001), while findings for tadalafil and vardenafil were not significant. Test of subgroup differences found no difference between male and female participants in the risk of AD.

conclusionsOur findings suggest that the use of PDE5Is is associated with a reduced risk of AD, highlighting its potential as a protective agent against neurodegenerative diseases. Given the very low quality of evidence and the heterogeneity among the included studies, further high-quality research is warranted to confirm these findings and elucidate the underlying mechanisms. Register number PROSPERO 2024: CRD42024522197.

Indexed as

Alzheimer DiseasePhosphodiesterase 5 InhibitorsHumansVardenafil DihydrochloridePhosphodiesterase 5 InhibitorsVardenafil DihydrochlorideAlzheimer's diseaseDementiaPDE5IsPhosphodiesterase type 5 inhibitorsSildenafilViagra

Identifiers

PMID38795271
PMCPMC11470851

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.